Les infections au SRAS-CoV-2 chez les enfants et les adolescents provoquent une maladie moins grave et moins de décès que chez les adultes. Bien qu'une évolution moins grave de l'infection soit un résultat positif, on s'inquiète du fait que des symptômes légers aient pu conduire à moins de t...ests, ce qui a entraîné un nombre moins important de cas identifiés de COVID-19 chez les enfants. Si les enfants présentant des symptômes légers ou inexistants transmettent la maladie, ils peuvent agir comme des vecteurs de transmission au sein de leur communauté. Il est essentiel de comprendre les symptômes, l'infectivité et les modes de transmission du SRAS-CoV-2 chez les enfants et les adolescents pour développer, adapter et améliorer les mesures de contrôle du COVID-19 à tous les âges. Ce document est un résumé des connaissances actuelles concernant l'acquisition et la transmission de l'infection par le SRAS-CoV-2 et les symptômes de la maladie COVID-19 chez les enfants et les adolescents. Il vise à éclairer les décisions, en fonction des contextes locaux, sur la meilleure façon de maintenir ouvertes les écoles, les jardins d'enfants et les crèches et sur les conseils à appliquer en matière de mixité intergénérationnelle.
more
La détection directe des protéines virales du SRAS-CoV-2 (antigènes) dans les écouvillons nasaux et autres sécrétions respiratoires à l'aide de tests immunologiques à flux latéral (également appelés tests de diagnostic rapide, TDR) offre une méthode plus rapide et moins coûteuse pour te...ster le SRAS-CoV-2 que la méthode de référence, les tests d'amplification des acides nucléiques (TAAN). Ces lignes directrices provisoires offrent des recommandations sur les utilisations prioritaires des tests de diagnostic rapide à détection d'antigène (TDR-Ag) dans des populations et des contextes spécifiques, notamment (i) pour la détection primaire des cas chez les personnes symptomatiques suspectées d'être infectées et les personnes asymptomatiques à haut risque de COVID-19, (ii) pour la recherche des contacts, (iii) pendant les enquêtes sur les épidémies et (iv) pour surveiller les tendances de l'incidence de la maladie dans les communautés. Les TDR-AG répondant aux exigences minimales de performance peuvent être utilisés en dehors des milieux cliniques et des laboratoires, y compris dans les communautés, par des opérateurs formés conformément aux instructions. Le guide fournit en outre des recommandations sur la mise en œuvre, la sélection des produits et le stockage
more
The second edition of the joint WHO, WIPO and WTO
publication “Promoting Access to Medical Technologies
and Innovation: Intersections between public health,
intellectual property and trade” (the Trilateral Study),*
published in 2020, included a special insert mappi...ng the
challenges posed by the COVID-19 pandemic in relation
to the integrated health, trade and IP policy framework set
out in the study. The Trilateral Study and the special insert
were designed to serve as background reference for policy-
makers in the widest sense – lawmakers, government
officials, delegates to international organizations, non-
governmental organizations (NGOs) and researchers
who seek a comprehensive presentation of the full range
of issues, including institutions and legal concepts with
which they may be unfamiliar. It is also designed to serve
as a factual resource for the three organizations’ technical
cooperation activities.
This update revises the information contained in that
insert in the light of more recent developments as of
30 August 2021. Further updates will be made to reflect
subsequent developments.
more
The African Development Bank has launched a consultation process with health ministers and other partners as it develops a strategy to drive enhanced access to health services across Africa through 2030.
Input from ministers in the Bank’s 54 regional member countries, development partners and c...ivil society is expected to strengthen the Bank’s Strategy for Quality Health Infrastructure in Africa (2021-2030). A robust scoping study titled “Good Health and Well-being” underpins the strategy.
more
La présente Stratégie pour des infrastructures sanitaires de qualité en Afrique2021-2030 (SISQA) répond à une demande des gouverneurs de la Banque africaine de développement (la BAD ou la Banque) invitant l’institution à définir son rôle dans la lutte contre les déficits d’infrastructu...res sanitaires en Afrique, en s’appuyant sur son expertise en matière de développement des infrastructures. Cette demande reconnaît que la santé joue un caractère central dans l’amélioration de la qualité de vie des Africains et l’opportunité de réaliser leur potentiel. Elle répond également à la demande croissante des pays membres régionaux (PMR), qui souhaitent que la Banque les aide à combler les lacunes en matière d’infrastructures sanitaires nationales, que la crise de la COVID-19 et d’autres crises sanitaires ont mises en évidence.
more
Brazilian media and science communicators must understand the main characteristics of misinformation in social media about COVID-19, so that they can develop attractive, up-to-date and evidence-based content that helps to increase health literacy and counteract the spread of false information.
The COVID-19 pandemic arrived in an evolving epidemiological context where some countries are experiencing a progressive decrease in HIV positivity in their testing programme as they are moving closer to the first 95 target. Distinguishing changes in HIV testing services due to the COVID-19 pandemic... from those resulting from evolving HIV testing strategies is crucial for adapting services and helping countries define their strategic mix of testing options moving forward. There is a need to focus, prioritize and plan for strategic efforts to prevent going further off the track toward achieving global targets and goals.
To support these efforts, WHO in partnership with ministries of health conducted an in-depth analysis of HIV testing services and antiretroviral therapy (ART) initiation prior to and during reported COVID-19 disruptions. Additional publicly available Global Fund and PEPFAR data was also reviewed and analysed. This analysis, and coordination with ministries of health, identified key service delivery adaptations utilized during COVID-19-related disruptions and formed the basis of this strategic guide.
This document focuses on current country needs, as well as plans for prioritization and potential surge support needs in the event of future disruptions. Although the data and implications are specific to sub-Saharan Africa, key principles and lessons can be applied elsewhere.
more
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...is document has been updated: version 15 March 2022.
more
11 august 2022, updated version
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...al dose of all WHO approved vaccines “since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease.”
People aged 60 and older who received the Sinovac and Sinopharm vaccines should get a third dose too, the experts added, though use of other vaccines may also be considered depending on supply and access.
“When implementing this recommendation, countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting in the oldest age groups”, they said.
SAGE has also reviewed a vaccine developed by Indian company Bharat Biotech and will issue a policy recommendation after WHO greenlights it for emergency use.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Временное руководство, Первый выпуск 8 января 2021 г., Обновлено 15 июня 2021 г., Обновлено 19 ноября 2021 г.
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
Climate Change 2021: The Physical Science Basis. Contribution of Working Group I to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change
The Lancet Countdown is an international collaboration that independently monitors the health consequences of a changing climate. Publishing updated, new, and improved indicators each year, the Lancet Countdown represents the
consensus of leading researchers from 43 academic institutions and UN ag...encies. The 44 indicators of this report expose an unabated rise in the health impacts of
climate change and the current health consequences of the delayed and inconsistent response of countries around the globe—providing a clear imperative for accelerated action that puts the health of people and planet above all else.The 2021 report coincides with the UN Framework Convention on Climate Change 26th Conference of the Parties (COP26), at which countries are facing pressure to realise the ambition of the Paris Agreement to keep the global average temperature rise to 1·5°C and to
mobilise the financial resources required for all countries to have an effective climate response. These negotiations unfold in the context of the COVID-19 pandemic—a global health crisis that has claimed millions of lives, affected livelihoods and communities around the globe, and exposed deep fissures and inequities in the world’s capacity to cope with, and respond to, health emergencies. Yet, in its response to both crises, the world is faced with an unprecedented opportunity to ensure a healthy future for all.
more
The unparalleled action needed to combat unprecedented inequality in the wake of COVID-19.
New billionaire minted every 26 hours, as inequality contributes to the death of one person every four seconds
Available in English, French, Spanish and Arabic https://www.oxfam.org/en/research/inequality-ki...lls
more
COVID-19 Management Guide -Version June 2021